You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Improved Reactor and Catalyst for Light Alkanes to Olefins and Liquid Fuels

    SBC: PRECISION COMBUSTION, INC.            Topic: C4722a

    C47-22a-271388Current manufacturing of ethylene via ethane steam reforming comes with significant energy and carbon emissions costs. A route to low carbon ethylene will have a meaningful impact as ethylene production is the largest world-wide and US chemical process in terms of production volumes, energy consumed, and carbon emitted. This project fits well within an overall strategy for decarboniz ...

    SBIR Phase II 2023 Department of Energy
  2. An Efficacy Trial of Mobile Technology for Reducing and Preventing Adolescent Suicide

    SBC: OUI THERAPEUTICS INC            Topic: 104

    ABSTRACT Suicide is a leading cause of death in the US and suicide rates have steadily increased. Despite this, there is a paucity of interventions that reduce suicide ideation and behavior. In this project, we seek to enhance a beta version of our suicide prevention digital therapeutic (developed in phase I) and conduct a randomized controlled trial to evaluate the efficacy of the digital therape ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Platform for the High Throughput Generation and Validation of Affinity Reagents

    SBC: ABBRATECH INC.            Topic: 300

    ABSTRACT We present a complete platform for the rapid generation and validation of recombinant mAbs. The innovations of this proposal include: (1) the pATHENA vector system for overnight conversion of phage display scFv or Fab clones into IgG molecules, (2) the Epivolve method for the isolation of site-specific Abs, (3) the incorporation of yeast display into pATHENA to allow biophysical measureme ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Development of TP-317 in Ulcerative Colitis

    SBC: Thetis Pharmaceuticals LLC            Topic: 300

    ABSTRACT Ulcerative colitis (UC) is a chronic, relapsing disease characterized by inflammation and ulceration of the colon and rectum that affects approximately 1.5 million people in the United States.1 Unfortunately, existing therapies have significant limitations. 5-ASA or mesalamine, which is approved as first-line therapy for UC, is effective in only 50% of UC patients and corticosteroids are ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Clinical Optimization of Ultrasonic Drug Delivery Technologies for Underserved Minority US Veterans in Chronic Pain

    SBC: ZETROZ SYSTEMS, LLC            Topic: 102

    Project Summary: Narcotic use in pain management of underserved minority populations and minority United States veterans has played a major role in the ongoing opioid crisis. According to the NIH, veterans are more susceptible to opioid addiction and are 40% more likely to suffer from severe chronic joint pain then non-veterans. Over the next decade, the percentage of minority veterans will increa ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. A novel monobody-drug conjugate to treat mutant Ras multiple myeloma

    SBC: TEZCAT Laboratories LLC            Topic: 102

    Tezcat is an early-stage, biopharmaceutical company developing novel biologics with a unique mechanism of action to treat the most recalcitrant cancers, such as mutant RAS multiple myeloma. Multiple myeloma is an incurable hematologic malignancy with an expected median survival of 7-8 years. Despite an initial response rate approaching 90% to proteasome inhibitor- containing combinations, all pati ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Optimized Ratiometric Voltage-Sensitive Dyes for Cardiac Research, Safety Pharmacology

    SBC: POTENTIOMETRIC PROBES LLC            Topic: 400

    Project Summary/Abstract Potentiometric Probes The overall goal of this Phase II SBIR project is to commercialize tools, invented by the founders of Potentiometric Probe, LLC, for high-fidelity optical recording of electrical activity in cardiac cells, tissues, and whole hearts. Potentiometric Probes develops organic voltage-sensitive dyes (VSDs) that convert the changes in voltage across cell mem ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Novel Broad-Spectrum Point-of-Care Coagulometer

    SBC: PEROSPHERE TECHNOLOGIES INC.            Topic: NHLBI

    Project Summary/Abstract Work under this proposal supports development of a broad-spectrum point-of-care (POC) coagulometer by Perosphere Technologies (The Perosphere Technologies POC Coagulometer) with the intent to create and offer an automated, microfluidic version of the manual Lee/White clotting time method. The device is based on novel technology and utilizes reagent-less, single-use microfl ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Extracorporeal Device 'Amytrapper' To Remove Beta Amyloid In Alzheimer'sDisease

    SBC: Recombinant Technologies LLC            Topic: NIA

    Abstract Alzheimer’s disease is the most common cause of dementia and fourth most common cause of death. Amyloid-beta (Aβ) plays a crucial role in initiation and progression of Alzheimer’s disease (AD). Removal of circulating Aβ would shift the equilibrium in Aβ levels between brain and blood towards blood. This shift would deplete brain amyloid levels and improve memory. Three commercial m ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Development of Targeted Damaging Agents for the Treatment of Drug-Resistant Gliomas

    SBC: KL50 THERAPEUTICS, LLC            Topic: 102

    PROJECT SUMMARY Loss of O6-methylguanine methyltransferase (MGMT) expression is common in cancers and confers sensitivity to DNA alkylators, such as temozolomide (TMZ). Epigenetic silencing of MGMT via promoter hypermethylation is found in ~50% of glioblastomas (GBMs), and in most lower grade gliomas with isocitrate dehydrogenase-1/2 (IDH1/2) mutations. MGMT is also silenced in other cancers, incl ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government